Structural Optimization of Pyrimidine‐Based EGFR Inhibitors Against Resistance Mutations in NSCLC
Drug Development Research · 2026-12 · 87 (8)
DOI: 10.1002/ddr.70408 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 17.11.2026. Verfasst von V M Megha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Sciences, Amrita School of Engineering, Amrita Vishwa Vidyapeetham, Bengaluru Campus, Bengaluru, India. Hauptthemen laut MEDLINE: Pyrimidines, Lung Neoplasms, Protein Kinase Inhibitors, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia.
Abstract (Originalsprache)
Non‐small cell lung cancer (NSCLC) remains a major global health burden, particularly among non‐smoking Asian populations, in whom activating EGFR mutations are the predominant oncogenic drivers. The emergence of multiple resistance mutations like the T790M, C797S, and especially the clinically intractable L858R/T790M/C797S triple mutant, has rendered all existing tyrosine kinase inhibitors (TKIs) ineffective. Despite substantial advances across three generations of EGFR‐TKIs, the therapeutic options available for resistant mutations remain limited. Currently no approved agent is capable of selectively and effectively targeting the triple mutant EGFR. This unmet clinical need highlights the urgency for continued drug discovery efforts aimed at overcoming resistance mediated by the C797S mutation. This need has driven intensive efforts toward developing inhibitors capable of overcoming C797S‐mediated resistance. Among the scaffolds explored, pyrimidine has emerged as particularly tractable, offering favorable ligand efficiency, synthetic accessibility and multiple substitution vectors that project into the T790M‐remodeled hydrophobic pocket and the region vacated by Cys797, while engaging the conserved Met793 of the hinge region. This review presents, an overview of the key structural features of the EGFR's ATP‐binding site is provided to facilitate a deeper understanding of the rational design of future EGFR inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physical Sciences, Amrita School of Engineering, Amrita Vishwa Vidyapeetham, Bengaluru Campus, Bengaluru, India.
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia.
- School of Pharmacy, Graphic Era Hill University, Dehradun, India.
- Centre for Promotion of Research, Graphic Era Deemed to be University, Dehradun, India.
- Department of Pharmaceutics, Vidya Siri College of Pharmacy, Bengaluru, India.
- Department of Biomedical Sciences, College of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia.
ORCID-Profile: V M Megha, Amrita Thakur, Sreeharsha Nagaraja, Kalicharan Sharma, Sujatha Tejavat
Förderung
- Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia
Zitieren
APA
Megha, V. M., Thakur, A., Nagaraja, S., Sharma, K., Gangadhar, N., & Tejavat, S. (2026). Structural Optimization of Pyrimidine‐Based EGFR Inhibitors Against Resistance Mutations in NSCLC. Drug Development Research, 87(8). https://doi.org/10.1002/ddr.70408
Vancouver
Megha VM, Thakur A, Nagaraja S, Sharma K, Gangadhar N, Tejavat S. Structural Optimization of Pyrimidine‐Based EGFR Inhibitors Against Resistance Mutations in NSCLC. Drug Development Research. 2026;87(8). doi:10.1002/ddr.70408
BibTeX
@article{Megha2026,
author = {Megha, V M and Thakur, Amrita and Nagaraja, Sreeharsha and Sharma, Kalicharan and Gangadhar, Nagesh and Tejavat, Sujatha},
title = {Structural Optimization of Pyrimidine‐Based EGFR Inhibitors Against Resistance Mutations in NSCLC},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {8},
doi = {10.1002/ddr.70408}
}
EUVIMED